Lupin Limited — Updates, 08-01-2025: Press Release

Lupin Limited has received an Establishment Inspection Report (EIR) from the U.S. FDA for its Pithampur Unit-1 facility, which manufactures both active pharmaceutical ingredients (APIs) and finished products. The inspection, conducted from September 16 to September 27, 2024, resulted in a classification of Voluntary Action Indicated (VAI). Managing Director Nilesh Gupta expressed satisfaction with the classification, underscoring the company's commitment to maintaining high-quality standards and compliance. This development enhances Lupin's operational credibility in the competitive pharmaceutical landscape and may further solidify its market position, providing a positive outlook for future business growth and investor confidence.